Mercados españoles cerrados en 4 hrs 46 min

InflaRx N.V. (IFRX)

NasdaqGS - NasdaqGS Precio en tiempo real. Divisa en USD
Añadir a la lista de favoritos
1,54000,0000 (0,00%)
Al cierre: 04:00PM EDT
1,5600 +0,02 (+1,30%)
Después del cierre: 04:34PM EDT

InflaRx N.V.

Winzerlaer Str. 2
Jena 07745
Germany
49 3641 508 180
https://www.inflarx.de

Sector(es)Healthcare
SectorBiotechnology
Empleados a tiempo completo62

Ejecutivos clave

NombreTítuloPagaEjecutadoAño de nacimiento
Dr. Niels C. Riedemann M.D., Ph.D.Co-Founder, CEO & Executive DirectorN/AN/A1973
Prof. Renfeng Guo M.D.Co-Founder, Chief Scientific Officer & Executive DirectorN/AN/A1970
Dr. Thomas Taapken Ph.D.Chief Financial OfficerN/AN/A1965
Ms. Derval O'CarrollSenior VP and Global Head of Regulatory Affairs & ComplianceN/AN/A1966
Dr. Camilla Chong M.D.Chief Medical OfficerN/AN/A1966
Mr. Jan Medina CFAHead of Investor Relations & VPN/AN/AN/A
Mr. Christian SchmidVP and Head of Legal Affairs & General CounselN/AN/AN/A
Ms. Nicole BertschSenior Director & Head of Human ResourcesN/AN/AN/A
Dr. Maria Habel PH.D.VP, Head of Preclinical R&D and QCN/AN/A1982
Dr. Bruce P. Burnett Ph.D.VP & Head of Medical AffairsN/AN/AN/A
Los importes son a partir de y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company also develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; and IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.

Gobierno corporativo

El ISS Governance QualityScore de InflaRx N.V., a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.